Palatin Technologies
James E. Hattersley serves as our SVP, Business Development, with primary responsibility for establishing strategic alliances and partnerships in therapeutic areas, including inflammatory disease, ophthalmology, and women's health categories.
Before Palatin, James served as SVP of Corporate Development at privately held Mission Pharmacal (urology, women's health), and as VP of Business Development at Santen, LTD (ophthalmology). Both Mission and Santen were preceded by Adherium, LTD, a global digital health asthma/COPD outcomes organization, where James was appointed SVP Business Development responsible for establishing Adherium North America (respiratory). Prior to Adherium, Mr. Hattersley held the position of Vice President of Business Development at Nektar Therapeutics and served for several years as Vice President of Business Development at Sun Pharmaceutical Industries.
This person is not in any offices
Palatin Technologies
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system.